Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development

Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting

Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies

Oligomerix to Present at Alzheimer’s Association International Conference

Oligomerix Appoints Chief Medical Officer William Erhardt, M.D., to Board of Directors

Oligomerix to Participate in Upcoming Life Sciences Conferences

Westchester County Association All Access Healthcare: Spotlight on Westchester’s Bioscience Ecosystem: Oligomerix

Oligomerix to Present at Upcoming Life Sciences Conferences

Fighting Neurodegeneration with Tau Tangle Blocking: Oligomerix CEO James Moe Explains

Oligomerix to Present at Clinical Trials on Alzheimer’s Disease Conference & Life Sciences Summit